The potential of AdAlta’s i-body platform to target G-Protein Coupled Receptors (GPCRs), the high hanging fruit of drug discovery, has recently been highlighted in two articles published by Nature Reviews Drug Discovery.
GPCRs have previously proven difficult to target by conventional therapeutics, namely small molecules and antibodies. Nature Reviews Drug Discovery has recently highlighted the achievement of a major milestone with Amgen’s erenumab securing FDA approval as the first antibody targeting a GPCR. However, the article also highlights the existing challenges and suggests that both phage display techniques as well as single-domain antibodies, characteristic of AdAlta’s i-body platform, may open up further opportunities to develop therapeutics to GPCRs.
Another article published in Nature Reviews Drug Discovery was focused on how conventional antibodies have captured the low-hanging fruit of drug discovery, resulting in blockbuster drugs such as Herceptin. However, next generation antibody therapeutics such as AdAlta’s i-body platform have the potential to reach the high-hanging fruit including difficult to access targets, multi-pass membrane proteins and improved antibody selectivity, as shown below.
The advantages of the i-body platform were discussed at AdAlta’s Investor Briefing held in February 2018 as well as in a recent report published by NDF Research.
